Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2298426 | 0.85 | CYP11B1 (0.46) | ALDH1A1GFERDYRK1AMAOB | |
| SCHEMBL19305485 | 0.84 | CHRM2 (0.50) | ALDH1A1GFERTAAR1ADRA1ADYRK1A | |
| SCHEMBL8132364 | 0.82 | POLB (0.46) | APLNRTAAR1ADRA1AKDM1AMAOA | |
| SCHEMBL590943 | 0.82 | APLNR (0.63) | ALDH1A1GFERAPLNRTAAR1ADRA1A | |
| SCHEMBL9676713 | 0.81 | ALDH1A1 (0.51) | ALDH1A1GFERAPLNRTAAR1ADRA1A | |
| SCHEMBL12509634 | 0.81 | MAOB (0.43) | APLNRTAAR1ADRA1AKDM1AMAOA | |
| SCHEMBL7331056 | 0.80 | KDM1A (0.40) | ALDH1A1GFERAPLNRTAAR1ADRA1A | |
| SCHEMBL7670936 | 0.80 | POLB (0.45) | APLNRTAAR1ADRA1AKDM1AMAOA | |
| SCHEMBL9921244 | 0.80 | TAAR1 (0.46) | APLNRTAAR1ADRA1AKDM1AMAOA | |
| SCHEMBL2425644 | 0.80 | TAAR1 (0.50) | APLNRTAAR1ADRA1AKDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099494-A1 | PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF, AND PREPARATION METHODS FOR AND USES OF PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2025-03-27 | — | — | US | disclosed |
| EP-4467552-A1 | PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF, AND PREPARATION METHODS FOR AND USES OF PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2024-11-27 | — | — | EP | disclosed |
| CN-118339172-A | Phosphonic acid compounds and prodrugs thereof, preparation method and application thereof | 上海海和药物研究开发股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2023138637-A1 | PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF, AND PREPARATION METHODS FOR AND USES OF PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF | 上海海和药物研究开发股份有限公司 | 2023-07-27 | — | — | WO | disclosed |
| CN-114736098-A | Chloro compound and preparation method thereof | 上海泰坦科技股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-3643709-B1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-10-20 | — | — | EP | disclosed |
| EP-3643709-B1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-10-20 | — | — | EP | disclosed |
| CN-111205268-B | Isoindoline derivative, intermediate thereof, preparation method, pharmaceutical composition and application | 康朴生物医药技术（上海）有限公司 | 2021-01-26 | — | — | CN | disclosed |
| CN-111205268-A | Isoindoline derivative, intermediate thereof, preparation method, pharmaceutical composition and application | 康朴生物医药技术（上海）有限公司 | 2020-05-29 | — | — | CN | disclosed |
| CN-105566290-B | Isoindoline derivative, intermediate thereof, preparation method, pharmaceutical composition and application | 康朴生物医药技术（上海）有限公司 | 2020-05-22 | — | — | CN | disclosed |
| EP-1223170-B1 | PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-20050171345-A1 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB, A SWEDEN CORPORATION | 2005-08-04 | — | — | US | disclosed |
| EP-1527051-A1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2005-05-04 | — | — | EP | disclosed |
| US-6875868-B2 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB (SE) | 2005-04-05 | — | — | US | disclosed |
| WO-2004011443-A1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | WO | disclosed |
| EP-1259512-B1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ASTRAZENECA AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| US-20030055250-A1 | Pteridine compounds for the treatment of psoriasis | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| EP-1259512-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| EP-1223170-A1 | PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001062758-A1 | PTERIDINE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055250-A1 | Pteridine compounds for the treatment of psoriasis | DHFR, NAMPT, HPRT1 | ALDH1A1 811/4885GFER 2682/4885APLNR 2694/4885 |
| US-20250099494-A1 | PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF, AND PREPARATION METHODS FOR AND USES OF PHOSPHONIC ACID COMPOUND AND PRODRUG THEREOF | ENPP1, ENPP3, PPA1 | ALDH1A1 1602/4885GFER 3311/4885APLNR 1388/4885 |
| US-20050171345-A1 | Pteridine compounds for the treatment of psoriasis | DHFR, NAMPT, HPRT1 | ALDH1A1 811/4885GFER 2682/4885APLNR 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.